In 2014, Japan approved Favipiravir for treating viral strains unresponsive to current antivirals.[18] Toyama Chemical initially hoped that Avigan would become a new influenza drug that could replace Tamiflu. However, animal experiments show the potential for teratogenic effects on fetuses, and the approval of production by The Ministry of Health, Labor and Welfare was greatly delayed and the production condition is limited only in an emergency in Japan.[19]
In March 2015, the US Food and Drug Administration completed a Phase III clinical trial studying the safety and efficacy of Favipiravir in the treatment of influenza.[20]
HomeSearch ResultsStudy Record Detail Save this study
Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02026349
Recruitment Status : Completed
First Posted : January 3, 2014
Last Update Posted : November 11, 2015
Sponsor:
MDVI, LLC
Collaborator:
MediVector, Inc.
Information provided by (Responsible Party):
MDVI, LLC
Study DetailsTabular View No Results PostedDisclaimerHow to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.